EZH2 and metastatic prostate carcinoma: A positive therapeutic effect of EZH2 inhibition has also been postulated in other types of cancer, and clinical trials are ongoing for various EZH2 inhibitors in breast cancer (NCT05633979), metastatic prostate cancer (NCT04388852, NCT04846478, NCT03460977), small cell lung cancer (NCT03460977) and urothelial and kidney cancer (NCT04388852).